Dr. Oron Frenkel Appointed Chairman of Clarius Mobile Health Medical Advisory Board

Dr. Oron Frenkel, an emergency physician, has been appointed to Clarius Mobile Medical Advisory Board. Dr. Oron Frenkel, a renowned POCUS education, will work to expand the use of ultrasound to improve healthcare and to ensure Clarius innovations focus on meeting the evolving demands of physicians.

“Point-of-care ultrasound is the most disruptive technology for clinicians since the stethoscope was invented 200 years ago. The image quality has become amazing and the applications for it are exploding,” said Dr. Frenkel. “Physicians are hungry for more rapid answers and definitive clarity on the pathologies their patients present with. Using handheld devices like Clarius at the bedside enables rapid diagnosis of many conditions and better guidance for procedures. I’m on a mission to expand its use.”

Dr. Frenkel will support the Clarius research and development team to ensure ultrasound devices are optimally designed for a variety of specialities. He will help launch a new Clarius Classroom that delivers educational webinars and training videos to enable more clinicians to learn to effectively use ultrasound.

“We’re excited to have Dr. Frenkel join us on our mission to improve patient care through the power of high definition medical imaging,” said Clarius CEO Laurent Pelissier, whose company pioneered handheld ultrasound with its first release in 2016. “His real-world experience will be invaluable to support our efforts in developing the best handheld ultrasound systems for every medical specialty.”

The Clarius team met Dr. Frenkel as part of a Canadian government’s Innovation Supercluster project for Point-of-Care Ultrasound, designed to bring handheld ultrasound to rural and acute care physicians across the province of British Columbia. As part of this program, 80 Clarius scanners have been deployed across the province, transforming the way remote areas deal with COVID-19 in their communities.

“Taking on the role as Chairman of the Medical Advisory Board puts me in a position to fuel my mission of developing and expanding the use of point-of-care ultrasound,” concluded Dr. Frenkel, “enabling new and current users to find better applications and ultimately deliver better patient care.”

Dr. Oron Frenkel completed his MS and MD at the University of California Joint Medical Program in Berkeley and San Francisco. He completed his residency in Emergency Medicine followed by a fellowship in Point-of-Care Ultrasound at Alameda County Medical Center in Oakland, California. Dr. Frenkel is currently an emergency physician and clinical assistant professor at the University of British Columbia based out of St. Paul’s Hospital and the UBC Department of Emergency Medicine.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”